I see our usual despot troll is well in control of all things CYP. Utterly clueless as usual.
Seems to have generated some continued buying interest in the market, contrary to our resident troll's assertions.
The results of this really worth commentating on beyond the miserable dialogue above. Only 51.1% wound reduction in the SoC control group. You know what that means. A few poor souls having their foot amputated. Whilst our clueless friend talks rubbish people's live are decimated, and those in the Cymerus group fortunate to be so in a randomised trial. Some 20% of people who get DFU's require amputation. That's likely 3 from this study control group on standard of care treatment alas, whilst our right old resident pest verbally defecates on these forums as usual for some reason, things of consequence happen in the real world.
"What Phase ? every phase is at least 5 years before the next is completed."
What an illiterate and ignorant chump by demonstration:
I would suspect, rather than a capital raise as suggested above, that CYP clearly has no pressing need for, this is a typical push to get some institutional investor interest or more strategic like buyers like Fidelity and BioSCience Managers. Personally I am grateful CYP publishes its Investor Presentations. Many companies pander to the big boy brokers and still don't even do retail investors the courtesy of sharing to their smaller investors.
Just as academic and Australian fiscal partnerships have developed, perhaps a commercial partnership instead likely. The language is pretty direct:
(20min delay)